PharmaVOICE - 
April 2017
Purchase Issue

In Every Issue
Letter from the Editor
Working in concert The act of collaborating with competitors, no [...]
By

Taren Grom, Editor

Upfront
Sunovion Teams up with Demi Lovato for Mental Health Documentary [...]
By

PharmaVOICE Staff

Innovator’s Corner
Developing a New Class of Therapeutics Kevin Lee, Ph.D., CEO [...]
By

Kevin Lee, Ph.D., CEO, Bicycle Therapeutics

HealthTech
Implant Wirelessly Supplies Power to the Brain Trend Watch: Micro [...]
By

PharmaVOICE Staff

Last Word
Defining Value for Payers Kelly Wilder, Executive VP, Managing Partner, [...]
By

Kelly Wilder, Executive VP, Managing Partner, Precision for Value

On The Cover

A New Era of Collaboration
This month’s special issue examines the new era of collaboration from R&D to commercialization and the role various players have in shaping the future of the life-sciences industry. According to a recent KPMG report, the majority of the 400 U.S. chief executives surveyed say the next three years will be more critical for industries than [...]
By

Taren Grom, Editor

Features

Collaborating A Necessary Component of Success
In 2009, PwC predicted that the pharma business model would evolve to a more patient-centric and collaborative approach by the year 2020. Three years from that deadline, there is plenty of evidence that the industry has started to collaborate both inside and outside of the “traditional” industry to help speed discovery and bring drugs to [...]
By

Robin Robinson

The Influence of Nontraditional Players
Nontraditional players have recognized the tremendous opportunity that lies in the healthcare space, and are innovating with or without pharma partners to solve many of the healthcare issues that patients are dealing with. Companies such as Apple, Google, General Electric, Samsung, Microsoft, and IBM are flooding the healthcare market with innovative approaches to medicine. Nontraditional [...]
By

Robin Robinson

R&D Partnerships
The pressure on the pharmaceutical industry to bring innovative medications to the market — as well as address issues related to access, cost, and value — is requiring new ways of doing research and development. Couple this with how quickly science is advancing and the volume of data that is being created from many sources, [...]
By

Denise Myshko

Collaboration within the Commercialization Process
According to a recent Strategy& report about how to overcome industry obstacles with a cross-functional strategy, beyond the many external challenges that pharma is facing that require collaboration with outside partners, pharma also must address divides within its internal commercial culture in order to be successful. As an industry that has long operated through silos [...]
By

Robin Robinson

Collaborating For Value
Changes across the healthcare industry are putting pressures on pharmaceutical companies to provide value to customers and stakeholders. Analysts and executives say the industry will have to watch the intertwining of provider, payer, digital, and pharma value chains closely as we enter an era that is focused on solutions versus product and where value is [...]
By

Denise Myshko

SHOWCASE FEATURE: Global Markets: Preparing for the Next Big Markets
According to PwC, the global pharmaceutical market will be worth almost .6 trillion by 2020. But with growth in mature markets slowing, a lot of the growth will come from emerging economies. In fact, according to McKinsey, emerging markets are expected to account for 0 billion in sales growth between 2015 and 2020. Already emerging [...]
By

PharmaVOICE Staff

Global Markets
Global markets have long held the promise of a rapid growth opportunity for the pharmaceutical industry, and indeed all forecasts continue to point to emerging markets being an engine of growth in volume and value of use of medicines. A closer look reveals that uptake of innovative medicines will continue to be driven by the [...]
By

Steve Mather, President Consulting, Europe, Cello Health Consulting

Speak Out
At the Forefront of Drug Discovery and Development: Small to Midsize Biotech/Biopharma Companies are the Leaders of Innovation  Today, the innovators of drug discovery and development often are found in the smaller, biotech and biopharma companies around the world. According to a report from HBM Partners AG, in the past several years, more than 60% [...]
By

Peter Benton, President and COO of Worldwide Clinical Trials

FEEDBACK